Bristol-Myers Squibb/$BMY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Primary listing
NYSE
Employees
32,500
Headquarters
Website
BMY Metrics
BasicAdvanced
$124B
17.55
$3.46
0.29
$2.49
4.15%
Price and volume
Market cap
$124B
Beta
0.29
52-week high
$63.33
52-week low
$42.52
Average daily volume
13M
Dividend rate
$2.49
Financial strength
Current ratio
1.255
Quick ratio
1.076
Long term debt to equity
241.7
Total debt to equity
274.414
Dividend payout ratio (TTM)
71.52%
Interest coverage (TTM)
7.95%
Profitability
EBITDA (TTM)
19,112.666
Gross margin (TTM)
72.62%
Net profit margin (TTM)
14.64%
Operating margin (TTM)
31.21%
Effective tax rate (TTM)
24.36%
Revenue per employee (TTM)
$1,480,000
Management effectiveness
Return on assets (TTM)
10.29%
Return on equity (TTM)
40.33%
Valuation
Price to earnings (TTM)
17.555
Price to revenue (TTM)
2.563
Price to book
6.67
Price to tangible book (TTM)
-5.23
Price to free cash flow (TTM)
9.618
Free cash flow yield (TTM)
10.40%
Free cash flow per share (TTM)
6.315
Dividend yield (TTM)
4.10%
Forward dividend yield
4.15%
Growth
Revenue change (TTM)
-0.22%
Earnings per share change (TTM)
-178.38%
3-year revenue growth (CAGR)
1.45%
10-year revenue growth (CAGR)
11.27%
3-year earnings per share growth (CAGR)
5.46%
10-year earnings per share growth (CAGR)
14.04%
3-year dividend per share growth (CAGR)
4.37%
10-year dividend per share growth (CAGR)
5.27%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
Business Wire·1 week ago
Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade
CNBC Television·2 weeks ago
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $124B as of February 17, 2026.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 17.55 as of February 17, 2026.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of February 17, 2026, the dividend rate is $2.49 and the yield is 4.15%. Bristol-Myers Squibb has a payout ratio of 71.52% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment date is unconfirmed.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.